Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 60.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,220 shares of the life sciences company's stock after selling 192,001 shares during the quarter. Worldquant Millennium Advisors LLC owned approximately 0.08% of Illumina worth $16,466,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Capital World Investors lifted its stake in Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. WCM Investment Management LLC raised its holdings in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after acquiring an additional 27,618 shares in the last quarter. Brown Advisory Inc. lifted its position in shares of Illumina by 54,220.9% in the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after acquiring an additional 1,909,118 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Illumina during the fourth quarter valued at $228,714,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 0.2%

NASDAQ:ILMN traded down $0.17 on Monday, hitting $80.37. 1,536,714 shares of the stock were exchanged, compared to its average volume of 2,326,484. The stock has a market cap of $12.72 billion, a PE ratio of -10.46, a PEG ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a fifty day moving average of $78.14 and a 200-day moving average of $108.39.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company's revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.98 EPS. As a group, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ILMN shares. Barclays cut their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Canaccord Genuity Group cut their price objective on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Finally, Guggenheim cut their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $128.15.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.